CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
复发/难治性滤泡性淋巴瘤患者后续治疗线数中的安全性
英文原题：Safety in Subsequent Lines of Therapy in Patients With Relapsed/Refractory Follicular Lymphoma.
查看英文原题
Safety in Subsequent Lines of Therapy in Patients With Relapsed/Refractory Follicular Lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
滤泡性淋巴瘤（FL）是一种通常以一线化学免疫治疗后慢性且连续复发为特征的疾病。尽管化学免疫治疗和联合治疗（如来那度胺联合利妥昔单抗）在FL的治疗序列中已得到充分确立，但仍需要简化治疗选择，并确定新型药物（如CAR-T 细胞疗法、zeste同源物2增强子抑制剂或磷酸肌醇3激酶抑制剂）在治疗格局中的定位。因此，本综述的目的是比较已批准药物在复发/难治性FL后续治疗线中的安全性特征，并评估不良事件的管理如何影响治疗选择。
展开英文摘要原文
Follicular lymphoma (FL) is a disease often characterized by chronic and successive relapses after first-line chemoimmunotherapy. Although chemoimmunotherapy and combination therapy, such as lenalidomide with rituximab, are well established in the treatment sequence of FL, there is a need to streamline treatment options and determine placement of novel agents, such as chimeric antigen receptor T-cell therapy, an enhancer of zeste homolog 2 inhibitor, or a phosphoinositide 3 kinase inhibitor, into the treatment landscape.
As such, the purpose of this review is to compare the safety profiles of approved agents in subsequent lines of therapy for relapsed or refractory FL and to assess how the management of adverse events may impact treatment choice.
论文信息
- 作者
- Bradley T、Davis M、Martin J、Woodward S
- 第一作者单位
- From Georgia Cancer Specialists, Atlanta, Georgia.Georgia
- 通讯作者单位
- H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.United States
- 文献类型
- 综述
- 期刊
- Journal of the advanced practitioner in oncology2024 Nov 5
- 原文标识
- PubMed 39802526 · DOI 10.6004/jadpro.2024.15.8.21
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →